← The Wire
AVTXNasdaq
Avalo Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1534120
Developing IL-1β-based treatments for immune-mediated inflammatory diseases, including their lead candidate abdakibart for hidradenitis suppurativa
red 8-K · 90d
$776M
Market cap
$19.29
Last close
+6.0%
1D
+12.9%
5D
1.6M
Volume
Price · last 39 sessions+40.0%
May 4L $12.74 · H $22.87Jun 29
300
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFA14AApr 10, 2026DEFA14ADEFA14AMay 1, 2025DEFA14ADEFA14AJun 27, 2024DEFA14ADEFA14AMar 28, 2024DEFA14ADEFA14ADec 7, 2023DEFA14ADEFA14AOct 19, 2023DEFA14ADEFA14AApr 25, 2022DEFA14ADEFA14AApr 27, 2021DEFA14ASCHEDULE 14AApr 28, 2020DEFA14ADEFA14AJun 19, 2019DEFA14ADEFA14AApr 18, 2018DEFA14ADEFA14A SUPPLEMENTApr 18, 2018DEFA14ADEFA14AApr 5, 2018
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $412K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Doyle MittieChief Medical Officer | Sell | 25,492 | $16.15 | $412K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 8,200 | $14.35 | $118K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 3,167 | $14.30 | $45K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance